CPRX Quote, Financials, Valuation and Earnings

Collegium Pharmaceutical, Inc. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 15.05%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat Collegium Pharmaceutical, Inc.'s return on equity of 24.26%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.86, signalling upside risk potential of 43.86%. On the other hand Collegium Pharmaceutical, Inc. has an analysts' consensus of $48.67 which suggests that it could fall by -0.36%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.685, which suggesting that the stock is 31.5% less volatile than S&P 500. In comparison Collegium Pharmaceutical, Inc. has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Collegium Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Collegium Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are smaller than Collegium Pharmaceutical, Inc. quarterly revenues of $209.4M. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is higher than Collegium Pharmaceutical, Inc.'s net income of $31.5M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.14x while Collegium Pharmaceutical, Inc.'s PE ratio is 30.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.32x versus 2.44x for Collegium Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 10.24%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.86, signalling upside risk potential of 43.86%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.32%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.685, which suggesting that the stock is 31.5% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.14x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.32x versus 7.27x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 81.15%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.86, signalling upside risk potential of 43.86%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $229.00 which suggests that it could fall by -9.62%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.685, which suggesting that the stock is 31.5% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.14x while Krystal Biotech, Inc.'s PE ratio is 38.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.32x versus 20.26x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of 35.57% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 40.17%. Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.86, signalling upside risk potential of 43.86%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.20 which suggests that it could grow by 16.52%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.685, which suggesting that the stock is 31.5% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.026%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $148.4M, which are larger than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Catalyst Pharmaceuticals, Inc.'s net income of $52.8M is higher than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 14.14x while Rigel Pharmaceuticals, Inc.'s PE ratio is 7.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 5.32x versus 2.86x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.